Properties
What is it?
Composition: 1ml of the preparation contains: Active substances: Dorzolamide hydrochloride (22.6mg) equivalent to 20mg dorzolamide, Timolol maleate (6.84mg) equivalent to 5mg timolol; Excipients: Hydroxyethylcellulose – 1.0mg, Citric acid monohydrate – 4.0mg, 1 M Sodium hydroxide solution – 0.066ml, Mannitol – 20mg, Benzalkonium chloride – 0.075mg, 1 M Sodium hydroxide solution – to pH 5.6±0.1 with 1 M Hydrochloric acid solution, Purified water – up to 1ml. Indications: Elevated intraocular pressure in open-angle glaucoma and pseudoexfoliative glaucoma when monotherapy is insufficiently effective. Contraindications: Hypersensitivity of the respiratory tract, bronchial asthma; severe chronic obstructive pulmonary disease; sinus bradycardia, sick sinus syndrome, sinoatrial block, atrioventricular block of II-III degree; severe heart failure; cardiogenic shock; severe renal failure, hyperchloremic acidosis; dystrophic processes of the cornea; pregnancy and lactation; childhood and adolescence; hypersensitivity to any component of the preparation. Precautions: Cardiovascular diseases in history, including heart failure; AV block of I degree; mild to moderate chronic obstructive pulmonary disease; severe forms of Raynaud's disease or Raynaud's syndrome; renal failure; elderly age; diabetes mellitus; urolithiasis; hyperthyroidism; corneal disorders. Pediatric use: Efficacy and safety in children under 18 years of age have not been studied. Dosage and administration: It is recommended that the patient instill one drop into the conjunctival sac of the eye (or both eyes) 2 times a day. If Glauvopt Forte is prescribed as a replacement for another ophthalmic preparation for glaucoma treatment, the latter should be discontinued 1 day before starting Glauvopt Forte. When used with other topical ophthalmic preparations, Glauvopt Forte should be administered at 10-minute intervals. During nasolacrimal occlusion (blinking), 2 minutes after instillation of the preparation, its systemic absorption is reduced, which can lead to an increase in local action. Glauvopt Forte is a sterile solution, so patients should be provided with instructions for the correct use of the bottle. The duration of treatment is determined by the doctor based on the patient's clinical condition. Contact lens use: Glauvopt Forte contains the preservative benzalkonium chloride, which can cause eye irritation. Therefore, patients should remove soft contact lenses before using the preparation and reinsert them 15 minutes after instillation. Benzalkonium chloride can discolor soft contact lenses. Dosage form: Eye drops 20mg/ml + 5mg/ml: Solution 5ml in a white or transparent polymer bottle with a dropper, closed with a polymer cap with a tamper-evident ring. One bottle with a dropper is placed in a cardboard box along with the instructions for use. Description: Clear, colorless or almost colorless, slightly viscous solution. Storage conditions: In a dry, protected from light, and inaccessible to children place, at a temperature not exceeding 25°C.